Threshold Pharmaceuticals Announces Promising Early Phase 1 Clinical Trial Results

Threshold Pharmaceuticals, Inc.

, today announced a preclinical collaboration with the MD Anderson Cancer Center and early Phase 1 clinical trial results of TH-302 in patients with advanced leukemias, which is also taking place at MD Anderson. TH-302 is a proprietary Hypoxia-Activated Prodrug (

) that specifically targets tumor hypoxia. The objectives of the Phase 1 trial are to determine the maximum tolerated dose (

), dose limiting toxicity (DLT), safety, tolerability, clinical activity and pharmacokinetics of TH-302 in patients with advanced leukemia. Eleven patients with either acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (

) have been enrolled in the trial to date. The starting dose in the trial was 120mg/m2 daily for 5 days of a 21-day cycle.